Zevra Therapeutics (ZVRA) is back on investors’ radar after presenting new real world and clinical data on its approved Niemann Pick disease type C therapy MIPLYFFA at the 22nd Annual WORLDSymposium, alongside progress in Europe.

Zevra’s share price has been choppy recently, with a 1 day share price return of 6.49% and a 7 day share price return of 5.64% around the WORLDSymposium data. Its 1 year total shareholder return of 6.09% sits against a much stronger 3 year total shareholder return of 53.96%, suggesting momentum has cooled in the short term after earlier gains.

If progress in rare disease treatments has your attention, it could be a good moment to see what else is out there through our screener of 25 healthcare AI stocks.

With Zevra trading at a steep discount to the average analyst price target and showing solid reported revenue and net income growth, the key question is whether this represents genuine mispricing or whether the market is already factoring in potential future gains.

Most Popular Narrative: 64% Undervalued

The most followed narrative puts Zevra’s fair value at $23.22, well above the last close of $8.36. It ties that gap to aggressive rare disease growth assumptions.

Zevra is well positioned to benefit from the increasing global prevalence and diagnosis of rare and neurodegenerative diseases, which is expanding Zevra's addressable market for its rare disease therapies like MIPLYFFA and pipeline assets, and should support future revenue growth.

The launch strategy for MIPLYFFA is gaining traction, as evidenced by rapid U.S. patient uptake (over 1/3 of diagnosed population after only two quarters), high retention rates, and expansion into new patient segments, indicating the potential for continued sequential revenue increases and greater earnings visibility as market penetration grows.

Curious how a small ultra orphan portfolio could justify such a large gap to fair value? The story leans heavily on sharp revenue expansion, a swing in profitability, and a future earnings multiple that looks closer to larger pharma names than a niche rare disease player. The full narrative spells out exactly how those moving parts connect.

Result: Fair Value of $23.22 (UNDERVALUED)

However, there are still clear pressure points, including slow OLPRUVA uptake with impairment charges and the very small MIPLYFFA patient pool, which concentrates revenue risk.

Build Your Own Zevra Therapeutics Narrative

If you are not fully on board with this storyline or prefer to stress test the numbers yourself, you can build a version that fits your view in just a few minutes, starting with Do it your way.

A great starting point for your Zevra Therapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Ready to hunt for your next idea?

If Zevra has you thinking more broadly about opportunities, do not stop here. There are other angles that might suit your portfolio just as well.

• Target value first and scan our 55 high quality undervalued stocks to see companies that the numbers suggest could trade below their current worth.
• Prioritize resilience and use the 81 resilient stocks with low risk scores to focus on businesses with lower risk scores that may suit a steadier approach.
• Spot potential early movers by checking our screener containing 25 high quality undiscovered gems, where smaller names with solid fundamentals might not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.